PD-Inhibitor (Nivolumab) and Ipilimumab followed by Nivolumab vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]

Protocol No
ALLIANCE-A031704-PDIGREE
Principal Investigator
Deepak Kilari
Phase
III
Summary
This study is being done to answer the following question: Can we prolong life for patients with advanced kidney cancer, by adding a drug called cabozantinib to another treatment after receiving the standard treatment? We are doing this study because we want to find out if this approach is better or worse than the usual approach for your advanced kidney cancer. The usual approach is defined as care most people get for advanced kidney cancer.
Description
This study is being done to answer the following question: Can we prolong life for patients with
advanced kidney cancer, by adding a drug called cabozantinib to another treatment after
receiving the standard treatment?
Participating Institutions
Froedtert Hospital
St. Joseph's Hospital - West Bend
Community Memorial Hospital
Status
OPEN TO ACCRUAL
Share This: